Intravenous immunoglobulin therapy for antibody deficiency
M T Nolte, B Pirofsky, G A Gerritz, B Golding, M T Nolte, B Pirofsky, G A Gerritz, B Golding
Abstract
Twenty patients with antibody deficiency were treated at random with either intramuscular immune serum globulin (ISG) or intravenous modified immune serum globulin (M-ISG). Fourteen patients received of 259 M-ISG infusions during 242 months of treatment. Catastrophic vasomotor reactions were not observed. A single dose of 150 mg/kilo M-ISG increased serum IgG values a mean 248 mg%. Intravenous M-ISG therapy was effective in reducing the incidence of acute infections. Subjects receiving M-ISG developed 0.103 acute infections per month of treatment. Patients injected with ISG had 0.295 acute infections per month of treatment. Seven subjects had separate courses of both intravenous M-ISG and intramuscular ISG. Acute infections per month of treatment for M-ISG and ISG were 0.104 and 0.406, respectively.
References
- Dtsch Med Wochenschr. 1962 Aug 24;87:1643-4 passim
- Vox Sang. 1962;7:157-74
- Am J Med. 1957 Dec;23(6):917-27
- Prog Hematol. 1956;1:318-29
- J Immunol. 1967 Jul;99(1):82-91
- Lancet. 1972 Jun 3;1(7762):1208-12
- Vox Sang. 1971 May;20(5):469-78
- Vox Sang. 1967 Jul;13(1):93-102
- Vox Sang. 1967 Jul;13(1):71-84
- Vox Sang. 1967 Jul;13(1):102-3
- N Engl J Med. 1968 Apr 25;278(17):919-23
- Can J Biochem. 1966 Mar;44(3):381-7
- N Engl J Med. 1966 Oct 13;275(15):826-31
- Australas Ann Med. 1969 Aug;18(3):271-6
- Birth Defects Orig Artic Ser. 1975;11(1):339-42
- Immunochemistry. 1965 Sep;2(3):235-54
Source: PubMed